Why is "Biosciences" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-21 01:16:51
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Biosciences entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-04-21 and was most recently seen on 2026-04-21.
Wikipedia Overview
This list of life sciences comprises the branches of science that involve the scientific study of life — such as animals, microorganisms, and plants. This is one of the two major branches of natural science, the other being physical science, which is concerned with non-living matter. Biology is the overall natural science that studies life, with the other life sciences as its sub-disciplines.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026 - BioSpace
-
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares - The Motley Fool
-
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data - MarketBeat
-
Artelo Biosciences (NASDAQ: ARTL) ends $6.5M at-the-market stock program - Stock Titan
-
Assessing Harmony Biosciences (HRMY) Valuation After Softer Earnings But Stronger Free Cash Flow - simplywall.st
-
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
-
Pulse Biosciences CEO Buys 15,000 Shares: SEC Filing Details | May 2026 - News and Statistics - IndexBox
-
Senti Biosciences Secures FDA Support for SENTI-202 Donor Selection Strategy in AML - The Clinical Trial Vanguard
-
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors. - The Globe and Mail
-
Forte Biosciences Stock: Targeting Celiac Disease (NASDAQ:FBRX) - Seeking Alpha
-
Newsflash: Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Have Been Trimming Their Revenue Forecasts - Yahoo Finance
-
MBX Biosciences (MBX) Is Down 20.8% After Wider Loss, Obesity Data And New CCO - Has The Bull Case Changed? - simplywall.st
-
DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates - PR Newswire
-
This biotech is testing an opioid designed to limit overdose risk - Stock Titan
-
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study - Yahoo Finance
-
Director Robert Duggan buys 660K Pulse Biosciences (PLSE) shares - Stock Titan
-
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results - PR Newswire
-
Non-opioid pain drug, GLP-1 companion highlight Artelo's 2026 plans - Stock Titan
-
UCSD receives $5M boost for recruitment efforts in medicine, biology, more - Times of San Diego
-
Arcadia Biosciences: Q1 Earnings Snapshot - Austin American-Statesman
-
Ben Lamm and Colossal Biosciences Are Building De-Extinction Science as a Back-Up Plan for Biodiversity - Colossal - colossal.com
-
Neurocrine Biosciences stock (US62886E1082): Q1 earnings beat and updated 2025 outlook in focus - AD HOC NEWS
-
Colossal Biosciences reveals new species for "de-extinction": the bluebuck - Axios
-
Colossal Biosciences Adds Bluebuck Antelope as Sixth De-Extinction Species - colossal.com
-
Todd Harris reports 2.91M shares in Tyra Biosciences (TYRA) - Stock Titan
-
Evofem Biosciences (EVFM) posts Q1 2026 loss and flags going-concern risk amid heavy debt - Stock Titan
-
These Analysts Just Made A Huge Downgrade To Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Forecasts - Yahoo Finance
-
Enveric Biosciences (ENVB) advances EB-003 and boosts cash in Q1 2026 - Stock Titan
-
Senti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia - Quiver Quantitative
-
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026 - PR Newswire
-
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia - PR Newswire
-
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Yahoo Finance
-
Colossal Biosciences announces ‘de-extinction’ plan for African bluebuck - CNN
-
[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan
-
Forte Biosciences (NASDAQ: FBRX) deepens Q1 loss while FB102 wins Fast Track - Stock Titan
-
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program - Yahoo Finance
-
Investors Can Find Comfort In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings Quality - simplywall.st
-
[8-K] Arcadia Biosciences, Inc. Reports Material Event - Stock Titan
-
TuHURA Biosciences, Inc. 1Q 2026: Revenue $0 Net loss $(7.54M), EPS $(0.13) — 10-Q Summary - TradingView
-
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update - PR Newswire
-
Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment - PR Newswire
-
Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure - The Globe and Mail
-
Arcadia Biosciences (RKDA) Q1 2026 loss deepens amid going concern risk - Stock Titan
-
Colossal Biosciences Is Working to Bring Back the Bluebuck, an Antelope Hunted to Extinction in 1800 - Colossal - colossal.com
-
Forte Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView
-
Investors Can Find Comfort In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings Quality - Yahoo Finance
-
Harmony Biosciences stock (US41319J1088): FDA approval and pipeline execution keep focus on growth - AD HOC NEWS
-
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders - Business Wire
-
App UAB, the University in your pocket - UAB Barcelona
-
Senti Biosciences (NASDAQ: SNTI) flags going concern, lines up $40M convertible note financing - Stock Titan
-
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia - PR Newswire
-
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million - Business Wire
-
Advanced mastocytosis trial data and JAK2 inhibitor at EHA 2026 - Stock Titan
-
Harmony Biosciences Holdings (HRMY) Announces Financial Results for Q1 2026 - Yahoo Finance
-
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology - PR Newswire
-
Mosaic cuts output as input costs soar, but bets on biosciences for future growth - AgTechNavigator.com
-
[SCHEDULE 13D/A] PULSE BIOSCIENCES, INC. Amended Major Shareholder Report - Stock Titan
-
Enveric Biosciences Releases Q1 2026 Financial Results - AlphaStreet
-
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees - GlobeNewswire
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
-
Pacific Biosciences stock (US6932471010): earnings volatility meets long-term sequencing hopes - AD HOC NEWS
-
Phase 1 CAR-T for lymphoma, myeloma set for EHA 2026 talks - Stock Titan
-
Leukemia cell therapy hits 50% remission with 'Donor X' - Stock Titan
-
AFOSR Space Biosciences Program Prepares to Launch Extremophiles to the ISS for POLARIS Mission - U.S. Embassy in Chile (.gov)
-
Governor Hochul Announces One Biosciences to Establish U.S. Operations in Albany - Empire State Development (ESD) (.gov)
-
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Mel - PR Newswire
-
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders - PR Newswire
-
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma - PR Newswire
-
Leukemia therapy SENTI-202 advances toward pivotal trial with up to $40M in new funding - Stock Titan
-
Cellectar Biosciences (CLRB) posts Q1 2026 loss and secures up to $140M - Stock Titan
-
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program - PR Newswire
-
Leverage, Covenants and Royalty Drain: Why Tuhura Biosciences’ Parkview Credit Deal Heightens Liquidity and Dilution Risks - TipRanks
-
Enveric Biosciences receives patent for psilocybin derivatives - Investing.com
-
Pulse Biosciences Co-Chairmen Purchase $13.3 Million in Company Stock - citybiz
-
Selecta Biosciences stock (US8162121084): merger with Cartesian and pipeline update move the story f - AD HOC NEWS
-
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hy - PR Newswire
-
Altesa BioSciences Closes Oversubscribed $75 Million Series B Financing to Transform Treatment of Chronic Lung Diseases - PR Newswire
-
Cellectar Biosciences (NASDAQ: CLRB) posts Q1 loss and flags going-concern risk - Stock Titan
-
Letter to the Duchenne Community - Solid Biosciences
-
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - PR Newswire
-
Colossal Biosciences Revives Bluebuck via Gene Editing - 조선일보
-
/C O R R E C T I O N -- BridGene Biosciences/ - PR Newswire
-
Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale - PR Newswire
-
Neurocrine Biosciences stock (US64125C1099): momentum after strong run in May and growing neuroscien - AD HOC NEWS
-
Ensysce Biosciences (ENSC) posts Q1 2026 loss, cash squeeze and strategic review - Stock Titan
-
Neurocrine Biosciences stock hits all-time high at 160.31 USD - Investing.com
-
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases - investor.lilly.com
-
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights - Yahoo Finance
-
Need To Know: Analysts Are Much More Bullish On Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenues - simplywall.st
-
BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation - Becton Dickinson
-
Caribou Biosciences stock (US1420381089): FDA study update draws attention - AD HOC NEWS
-
Avidity Biosciences Announces Expected Record Date for Spin-Off - PR Newswire
-
New Forte Biosciences hire gets 50K options, 50K RSUs to join - Stock Titan
-
Pulse Biosciences director Robert W. Duggan acquires $13m in stock - Investing.com Australia
-
Jade Biosciences Inc - Prospectus filed for resale of up to 39,542,339 shares by selling stockholders - SEC filing - marketscreener.com
-
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations - PR Newswire
-
Pulse Biosciences (NASDAQ: PLSE) CEO adds 15,000 shares in open-market buy - Stock Titan
-
Stifel raises MBX Biosciences stock price target to $56 on obesity data - Investing.com
-
[10-Q] Xenetic Biosciences, Inc. Quarterly Earnings Report - Stock Titan
-
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - PR Newswire
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.